Slide 1: Analyst / Investor Conference FY 2011 Results and Guidance 2012
Analyst / Investor Conference FY 2011 Results and Guidance 2012 February 8, 2012 03:00 p.m. CET Uwe Röhrhoff, CEO Jürgen Wiecha, CFO
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Agenda
Agenda Review FY 2011 Uwe Röhrhoff, CEO Financial Overview FY 2011 Jürgen Wiecha, CFO Guidance FY 2012 Uwe Röhrhoff, CEO 3
Slide 4: FY 2011: Healthy growth of key figures
FY 2011: Healthy growth of key figures Key group figures in EUR m, EPS and dividend in EUR Revenues adjusted EBITDA FXN: + 7.8% adjusted EBITDA Margin + 6.8% + 6.3% 20.0% 19.9% adjusted EPS Dividend per share + 25.1% + 20.0% Proposed 4
Slide 5: FY 2011 targets achieved
FY 2011 targets achieved Upgraded Guidance FY 2011 Guidance FY 2011 Actual results (as of July 13, 2011) (as of Oct. 6, 2011) FY 2011 Revenues + 6% to 7%1 at const. FX + 7% to 8%1 at const. FX + 7.8%1 at const. FX Adj. EBITDA margin About 20.0% About 20.0% 19.9% Capex About EUR 80m About EUR 85m
Slide 6: Agenda
Agenda Review FY 2011 Uwe Röhrhoff, CEO Financial Overview FY 2011 Jürgen Wiecha, CFO Guidance FY 2012 Uwe Röhrhoff, CEO 6
Slide 7: FY 2011 P&L Overview
FY 2011 P&L Overview FY 2011 FY 2010 Change EUR m EUR m in % Revenues 1,094.7 1,024.8 +6.8 Adjusted EBITDA1 217.3 204.5 +6.3 EBITA 129.9 119.8 +8.4 Amortization of FV adjustments 20.6 24.8 -16.9 Profit before interest and taxes (EBIT) 109.3 95.0 +15.1 Financial result -36.8 -34.3 -7.3 Profit before
Slide 8: FY 2011: Revenues by division
FY 2011: Revenues by division FY 2011 Change Change in % at EUR m in % const. FX Total Group 1,094.7 +6.8 +7.8 Tubular Glass 304.1 -2.0 -0.2 Plastic Systems 371.4 +20.6 +20.3 Moulded Glass 342.4 +4.6 +5.5 Life Science Research 91.8 -3.3 +0.4 8
Slide 9: FY 2011: Adjusted EBITDA and margin by division
FY 2011: Adjusted EBITDA1 and margin by division FY 2011 FY 2010 Change Margin Margin EUR m in % in % in % Total Group 217.3 +6.3 19.9 20.0 Tubular Glass 62.4 -11.2 20.5 22.6 Plastic Systems 87.1 +17.5 23.4 24.1 Moulded Glass 76.8 +13.1 22.4 20.7 Life Science Research 10.6 -9.5 11.5 12.3 1 Earnings
Slide 10: Key balance sheet figures
Key balance sheet figures Nov 30, 2011 Nov 30, 2010 Change EUR m EUR m in % Equity 552.2 529.4 +4.3 Equity ratio in % 36.4 39.0 Net Working Capital1 172.5 151.2 +14.1 in % of LTM revenues 15.8 14.8 Net Financial Debt2 364.6 311.0 +17.2 Adj. EBITDA Leverage 1.7 1.5 +13.3 1 Inventories (incl. prepayme
Slide 11: Long-term financing structure with ample financial leeway
Long-term financing structure with ample financial leeway Comparison of debt/cash positions in EUR m 364.6 Interest rate (due date) Net Financial Debt 311.0 300.0 Fixed coupon at 5.0% (2018) Bond 126.0 Long-term bank debt 183.9 Interest rate hedged at 3.26% 154.7 (2016) Revolving bank debt 10.0 0.0
Slide 12: Q4 2011: Revenues by division
Q4 2011: Revenues by division Q4 2011 Change Change in % at EUR m in % const. FX Total Group 288.4 +6.1 +6.9 Tubular Glass 79.1 +4.0 +4.8 Plastic Systems 98.0 +13.6 +14.8 Moulded Glass 91.3 +3.3 +3.6 Life Science Research 23.6 -6.5 -5.2 12
Slide 13: Q4 2011: Adjusted EBITDA and margin by division
Q4 2011: Adjusted EBITDA1 and margin by division Q4 2011 Q4 2010 Change Margin Margin EUR m in % in % in % Total Group 62.2 +10.1 21.6 20.8 Tubular Glass 16.1 +12.6 20.4 18.8 Plastic Systems 26.0 +14.0 26.5 26.4 Moulded Glass 22.6 +12.4 24.8 22.8 Life Science Research 2.3 -43.9 9.7 16.3 1 Earnings b
Slide 14: Agenda
Agenda Review FY 2011 Uwe Röhrhoff, CEO Financial Overview FY 2011 Jürgen Wiecha, CFO Guidance FY 2012 Uwe Röhrhoff, CEO 14
Slide 15: Our most comprehensive product portfolio for pharma and healthcare
Our most comprehensive product portfolio for pharma and healthcare Primary Pharmaceutical Packaging Medical Devices Storage and transport of liquid and solid drugs Storage and safe drug dosage and administration Ampoules, vials, Inhalers cartridges Insulin pens Pharma glass bottles Glass s
Slide 16: FY 2012: Continued investments in healthy growth
FY 2012: Continued investments in healthy growth Growth investments in Tubular Glass Continued investments: 4th production line for prefillable glass syringes Incremental investments in quality inspection technology Growth investments in Medical Plastic Systems Capacity expansion in German
Slide 17: FY 2012: Operational preview
FY 2012: Operational preview Tubular Glass: Back to normal revenue growth Modest enhancement of adjusted EBITDA margin Plastic Systems: Strong organic growth driven by product and tooling business Adjusted EBITDA margin slightly softer because of strong tooling business Moulded Glass:
Slide 18: Guidance FY 2012
Guidance FY 2012 FY 2011 Guidance FY 2012 as reported + 5% to 6% at const. FX Revenues EUR 1,094.7m1 + 7% to 8% nominal2 Adj. EBITDA margin 19.9% About 19.5% Capex EUR 86.2m About EUR 100m 1 Average exchange rate for FY 2011: EUR 1.00 = USD 1.395 2 Assumed average exchange rate for FY 2012: EUR 1.00
Slide 19: Capital Markets Day 2012
Capital Markets Day 2012 Date July 11+12, 2012 Location Horsovsky Tyn, Czech Republic Registration Invitations will be sent out shortly 19
Slide 20: Financial Calendar
Financial Calendar April 12, 2012 Interim Report 1st Quarter 2012 April 26, 2012 Annual General Meeting July 11, 2012 Interim Report 2nd Quarter 2012 July 11+12, 2012 Capital Markets Day 2012 October 4, 2012 Interim Report 3rd Quarter 2012 20
Slide 21: Investor Relations & Creditor Relations contact details
Investor Relations & Creditor Relations contact details Phone +49 211 6181-257 Fax +49 211 6181-121 E-mail gerresheimer.ir@gerresheimer.com IR website www.gerresheimer.com/ir 21
Slide 22: Backup
GERRESHEIMER Backup
Slide 23: Full-year reconciliation from adjusted EBITDA to net income
Full-year reconciliation from adjusted EBITDA to net income FY 2011 FY 2010 EUR m EUR m Adjusted EBITDA 217.3 204.5 Restructuring expenses 0.1 3.7 One-off income/expense -6.9 0.0 EBITDA 210.3 200.8 Amortization of fair value adjustments 20.6 24.8 Depreciation 80.4 81.0 Profit before interest and tax
Slide 24: Fourth quarter reconciliation from adjusted EBITDA to net income
Fourth quarter reconciliation from adjusted EBITDA to net income Q4 2011 Q4 2010 EUR m EUR m Adjusted EBITDA 62.2 56.6 Restructuring expenses 0.1 0.0 One-off income/expense -5.1 0.8 EBITDA 57.0 57.4 Amortization of fair value adjustments 6.5 6.2 Depreciation 19.6 19.6 Profit before interest and taxe